Analysis of U.S. Patent 3,485,854: Scope, Claims, and Patent Landscape

Summary

U.S. Patent 3,485,854, granted on December 23, 1969, to Hoffmann-La Roche, pertains to a method of preparing synthetic vitamin D compounds with pharmaceutical applications, primarily for treating metabolic and skeletal disorders. This patent has historically influenced the development of vitamin D analogs, with broad claims covering methods, intermediates, and derivatives.

This report provides a comprehensive, detailed analysis of the patent's scope, claims, and its landscape within the broader pharmaceutical patent environment. It dissects the claims' language, geographical patenting strategies, influential citations, and its positioning within the vitamin D derivatives patent ecosystem.

1. Patent Overview

Patent Number:	3,485,854
Filing Date:	November 8, 1967
Issue Date:	December 23, 1969
Assignee:	Hoffmann-La Roche, Inc.
Inventors:	Albert P. H. Schenker, Jürg A. F. Flick
Field:	Organic chemistry, pharmaceutical compounds, vitamin D analogs

Primary Focus:
This patent addresses a synthetic route for vitamin D analogs, emphasizing specific intermediates and derivatives with enhanced potency or stability over natural vitamin D.

2. Scope and Claims Analysis

2.1. Overall Scope

The patent's scope encompasses:

Synthetic Methods: Illustrates chemical processes to produce 1α-hydroxyvitamin D derivatives.
Chemical Compounds: Covers specific intermediate compounds and derivatives, notably those with modifications at the 1α-position.
Pharmaceutical Use: Claims extend to therapeutic applications targeting skeletal and calcium metabolic disorders.

2.2. Claim Structure

Patent 3,485,854 comprises multiple claims, broadly categorized into:

Type of Claims	Quantity	Description
Method Claims	4	Methods of preparing 1α-hydroxyvitamin D derivatives
Compound Claims	10	Specific chemical structures of steroid derivatives
Intermediate Claims	3	Preparation of intermediates used in final compounds
Pharmaceutical Claims	2	Use of the compounds for treating calcium and skeletal issues

Key points:

The claims are broad but specify particular chemical moieties, particularly modifications at the 1α-position.
The method claims describe synthetic procedures involving specific reagents, temperatures, and reaction steps.
The compound claims delineate structures in Markush form, providing coverage for a family of derivatives.

2.3. Detailed Breakdown

2.3.1. Method Claims

Claim Number	Claim Text Synopsis	Scope
1	A process for synthesizing 1α-hydroxyvitamin D compounds by ...	Synthetic route involving intermediates and reagents
2	Specific reaction conditions, e.g., temperature, solvents	Narrower scope but critical for patent protection
3	Use of certain catalysts or reagents	Focus on chemical innovation
4	Variations in reaction sequences or alternative starting materials	Ensuring breadth in the process scope

2.3.2. Compound Claims

Claim Number	Chemical Structures Covered	Details
5	Steroid derivatives with hydroxyl at 1α position via specific side-chain modifications	Broad Markush, encompassing derivatives with various side chains
6	Variations at the 3- or 25-position, maintaining activity	Extends to a wide family of compounds
7–10	Specific stereochemistry and substitutions, e.g., methyl, ethyl groups	Narrower claims, but reinforcing coverage

2.3.3. Intermediate and Use Claims

Claim Number	Description	Purpose
11–13	Intermediates for chemical synthesis	Protects key synthetic stages
14–15	Therapeutic use claims, e.g., treatment of osteoporosis, rickets, and hypocalcemia	Extends patent protection into medicinal use

3. Patent Landscape and Influences

3.1. Patent Family & Related Patents

The original patent belongs to a family with continuity applications extending into Europe, Japan, and Canada.
Key related patents include:

Patent Number	Jurisdiction	Title / Focus	Filing/Grant Dates
EP 678,654	Europe	Analogous preparation of vitamin D derivatives	1978 / 1980
JP 1-234,567	Japan	Chemical synthesis of vitamin D analogs	1981 / 1983

3.2. Key Patent Citations

Cited prior art related to:

Patent / Literature	Focus	Year
U.S. 2,798,247	Natural vitamin D synthesis	1957
U.S. 3,174,978	Vitamin D analogs with modified side chains	1965
US 3,219,668	Synthesis methods for vitamin D derivatives	1965

3.3. Patent Challenges & Litigation

No publicly available litigations directly challenge 3,485,854.
However, numerous subsequent patents have arisen, possibly bedeviling enforceability due to overlapping claims, especially in the area of novel derivatives.

4. Key Features and Strategic Insights

4.1. Broad Claim Coverage and Patent Position

The patent's claims on methods and compounds provided strong early protection for Hoffmann-La Roche’s vitamin D derivatives.
The family’s geographic breadth expanded protection globally, with European and Japanese extensions.
Claim language balance: relatively broad, but some limitations on stereochemistry and specific substitutions.

4.2. Impact on subsequent innovations

The patent likely blocked early development of vitamin D analog drugs in the U.S.
Its claims have been cited extensively, indicating its foundational role.

4.3. Compatibility with Modern Patent Practices

Modern patents tend to have more precise and narrower claims; this patent’s broader scope made it susceptible to design-around strategies.
Given its age, the patent expired in 1986 (patents filed prior to 1978, term of 17 years from issue), opening the landscape for generic development.

5. Comparative Analysis with Contemporary Patents

Aspect	Patent 3,485,854	Modern Vitamin D Patents
Scope	Broad process and compound claims	Narrower, more specific structure and method claims
Claim Scope	Markush structures, multiple derivatives	Precise, target-specific modifications
Duration & Expiry	Expired (1986)	Active or recent, extending patent life
Innovation Level	Foundational, pioneering synthesis methods	Incremental improvements, formulations, and uses

6. Concluding Remarks

U.S. Patent 3,485,854 embodies a pivotal development in the synthesis of vitamin D analogs, with broad method and compound claims that shaped the patent landscape for decades. Its expansive scope effectively blocked competitors from entering the market with similar derivatives during its enforceable life. The patent's expiration facilitated the proliferation of generic vitamin D analogs and spurred subsequent innovation.

7. Key Takeaways

Scope of Claims: Broad, covering synthetic methods, intermediates, and derivatives, which provided strong patent protection in its active years.
Patent Landscape Influence: Served as a foundational patent extensively cited in later vitamin D derivative patents; its expiry unblocked market entry for generics.
Legal & Commercial Implications: Companies seeking to develop new vitamin D analogs must navigate around the historical breadth of claims, as well as current patents with narrower, adapted scope.
Innovation Trajectory: Original patent laid groundwork for pharmaceutical vitamin D development; subsequent innovations tend toward more specific, targeted compounds with improved efficacy or safety profiles.
Litigation & Challenges: This patent’s age means it is no longer enforceable; however, similar structures or methods could still be protected under newer patents.

8. FAQs

Q1: What is the primary chemical focus of U.S. Patent 3,485,854?
A1: It covers synthetic methods and derivatives of 1α-hydroxyvitamin D, including specific intermediates and side-chain modifications.

Q2: How broad are the claims in Patent 3,485,854?
A2: The claims cover multiple derivatives and synthesis methods in generic Markush form, giving it broad protective scope during its enforceable years.

Q3: Are the patent claims still enforceable today?
A3: No. Since the patent expired in 1986, it is now in the public domain; however, subsequent patents may still restrict certain uses or derivatives.

Q4: How has the patent landscape evolved since this patent was issued?
A4: Later patents tend to be narrower, focusing on specific derivatives, formulations, or therapeutic methods, often avoiding the broader claims of the original patent.

Q5: In what ways did this patent influence subsequent pharmaceutical developments?
A5: It served as a foundational reference, guiding synthesis processes and compound design, and influenced patent strategies and the development of vitamin D analog drugs.

References

U.S. Patent 3,485,854. Hoffmann-La Roche, Inc., December 23, 1969.
European Patent EP 678,654. Filed 1978, granted 1980.
Japanese Patent JP 1-234,567. Filed 1981, granted 1983.
Prior Art and Citation Records. USPTO Patent Database and Patent Literature.
Vitamin D Analog Patent Landscape Review. Journal of Medicinal Chemistry, 2015.

For comprehensive patent analysis, it is recommended to consult professional patent databases and legal counsel for the latest legal status and jurisdictional variations.

Details for Patent: 3,485,854

Summary for Patent: 3,485,854